CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 2,231 enrolled
Drug / intervention
Lasmiditan 100 mg +2 moredrug
Likely dose
Lasmiditan 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02439320
NCT02439320Phase 3Completed
CompareCT.gov

A Study of Two Doses of LAsMiditan (100 mg and 200 mg) Compared to Placebo in the AcUte Treatment of MigRAIne: A Randomized, Double-blind, Placebo-controlled Parallel Group Study

Eli Lilly and Company·interventional·Posted May 8, 2015·Updated Dec 16, 2019

In Brief

A Phase 3 clinical trial evaluating Lasmiditan 100 mg, Lasmiditan 200 mg, and 1 other intervention for Acute Migraine. Completed, enrolled 2,231 participants across 92 sites.

Detailed Summary

This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Migraine
CountriesUnited States
CollaboratorsCoLucid Pharmaceuticals

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 8, 2015
Enrollment StartApr 1, 2015
Primary CompletionJul 1, 2016
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.2 years ago

Interventions

Lasmiditan 100 mgdrug

Lasmiditan 200 mgdrug

Placebo (matches lasmiditan doses)drug